{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:00Z","timestamp":1786980540837,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10072-026-09187-x","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:25:40Z","timestamp":1781936740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of neurofilament light chain protein and glial fibrillary acidic protein in multiple sclerosis subtypes and disease activity patterns: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"given":"Cheng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8316-4988","authenticated-orcid":false,"given":"Youhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"2","key":"9187_CR1","first-page":"126","volume":"87","author":"G Disanto","year":"2016","unstructured":"Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T, Evdoshenko E, Thouvenot E, Trojano M, Norgren N, Teunissen C (2016) Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 87(2):126\u20139","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"9187_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037297","volume":"103","author":"M Haki","year":"2024","unstructured":"Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA (2024) Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment. Medicine 103(8):e37297","journal-title":"Medicine"},{"issue":"6","key":"9187_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Sch\u00e4delin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81(6):857\u201370","journal-title":"Ann Neurol"},{"issue":"4","key":"9187_CR4","volume":"7","author":"T Uher","year":"2020","unstructured":"Uher T, Schaedelin S, Srpova B, Barro C, Bergsland N, Dwyer M, Tyblova M, Vodehnalova K, Benkert P, Oechtering J, Leppert D (2020) Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology & Neuroinflammation 7(4):e714","journal-title":"Neurology: Neuroimmunology & Neuroinflammation"},{"issue":"19","key":"9187_CR5","doi-asserted-by":"publisher","first-page":"e1898","DOI":"10.1212\/WNL.0000000000012752","volume":"97","author":"C Bridel","year":"2021","unstructured":"Bridel C, Leurs CE, van Lierop ZY, van Kempen ZL, Dekker I, Twaalfhoven HA, Moraal B, Barkhof F, Uitdehaag BM, Killestein J, Teunissen CE (2021) Serum neurofilament light association with progression in natalizumab-treated patients with relapsing-remitting multiple sclerosis. Neurology 97(19):e1898\u2013e1905","journal-title":"Neurology"},{"issue":"3","key":"9187_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","volume":"32","author":"BA Cree","year":"2019","unstructured":"Cree BA, Mares J, Hartung HP (2019) Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol 32(3):365\u201377","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"9187_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u201373","journal-title":"Lancet Neurol"},{"issue":"5","key":"9187_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BA Cree","year":"2019","unstructured":"University of California, San Francisco MS-EPIC Team, Cree BA, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N (2019) Silent progression in disease activity\u2013free relapsing multiple sclerosis. Ann Neurol 85(5):653\u201366","journal-title":"Ann Neurol"},{"issue":"10","key":"9187_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(07)70243-0","volume":"6","author":"DH Miller","year":"2007","unstructured":"Miller DH, Leary SM (2007) Primary-progressive multiple sclerosis. Lancet Neurol 6(10):903\u201312","journal-title":"Lancet Neurol"},{"issue":"2","key":"9187_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S1474-4422(18)30460-5","volume":"18","author":"O Ciccarelli","year":"2019","unstructured":"Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG, Amato MP, Banwell B, Barkhof F, Bebo B, Becher B, Bethoux F, Brandt A (2019) Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurol 18(2):185\u201397","journal-title":"Lancet Neurol"},{"issue":"12","key":"9187_CR11","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1177\/13524585221114441","volume":"28","author":"T Williams","year":"2022","unstructured":"Williams T, Tur C, Eshaghi A, Doshi A, Chan D, Binks S, Wellington H, Heslegrave A, Zetterberg H, Chataway J (2022) Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: analysis from the MS-STAT randomised controlled trial. Mult Scler J 28(12):1913\u201326","journal-title":"Mult Scler J"},{"issue":"9","key":"9187_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1177\/1352458516677592","volume":"23","author":"F Sacc\u00e0","year":"2017","unstructured":"Sacc\u00e0 F, Costabile T, Carotenuto A, Lanzillo R, Moccia M, Pane C, Russo CV, Barbarulo AM, Casertano S, Rossi F, Signoriello E (2017) The EDSS integration with the brief international cognitive assessment for multiple sclerosis and orientation tests. Mult Scler J 23(9):1289\u201396","journal-title":"Mult Scler J"},{"issue":"9","key":"9187_CR13","doi-asserted-by":"publisher","first-page":"e209357","DOI":"10.1212\/WNL.0000000000209357","volume":"102","author":"RJ Fox","year":"2024","unstructured":"Fox RJ, Cree BA, de S\u00e8ze J, Gold R, Hartung HP, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Singh CM, Altincatal A (2024) Temporal relationship between serum neurofilament light chain and radiologic disease activity in patients with multiple sclerosis. Neurology 102(9):e209357","journal-title":"Neurology"},{"issue":"1","key":"9187_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000926","volume":"8","author":"M Saraste","year":"2020","unstructured":"Saraste M, Bezukladova S, Matilainen M, Tuisku J, Rissanen E, Sucksdorff M, Laaksonen S, Vuorimaa A, Kuhle J, Leppert D, Airas L (2020) High serum neurofilament associates with diffuse white matter damage in MS. Neurol Neuroimmunol Neuroinflamm 8(1):e926","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"9187_CR15","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acn3.638","volume":"5","author":"T Chitnis","year":"2018","unstructured":"Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N (2018) Neurofilament light chain serum levels correlate with 10\u2010year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol 5(12):1478\u201391","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"9187_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/acn3.51969","volume":"11","author":"A Abdelhak","year":"2024","unstructured":"Abdelhak A, Antweiler K, Kowarik MC, Senel M, Havla J, Zettl UK, Kleiter I, Skripuletz T, Haarmann A, Stahmann A, Huss A (2024) Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis. Ann Clin Transl Neurol 11(2):477\u201385","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"9187_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.27096","volume":"97","author":"P Benkert","year":"2025","unstructured":"Benkert P, Maleska Maceski A, Schaedelin S, Oechtering J, Zadic A, Vilchez Gomez JF, Melie-Garcia L, Cagol A, Galbusera R, Subramaniam S, Lorscheider J (2025) Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B\u2010Cell Depleting Treatment in Multiple Sclerosis. Ann Neurol 97(1):104\u2013115","journal-title":"Ann Neurol"},{"issue":"3","key":"9187_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier S, Willemse EA, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, Cagol A, Barakovic M, Galbusera R, Subramaniam S, Barro C (2023) Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol 80(3):287\u2013297","journal-title":"JAMA Neurol"},{"issue":"11","key":"9187_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41582-021-00556-y","volume":"17","author":"N Koch-Henriksen","year":"2021","unstructured":"Koch-Henriksen N, Magyari M (2021) Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Reviews Neurol 17(11):676\u2013688","journal-title":"Nat Reviews Neurol"},{"key":"9187_CR20","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. ;339","DOI":"10.2427\/5768"},{"issue":"12","key":"9187_CR21","doi-asserted-by":"publisher","first-page":"7494","DOI":"10.1007\/s00415-024-12701-w","volume":"271","author":"S Malucchi","year":"2024","unstructured":"Malucchi S, Bava CI, Valentino P, Martire S, Lo Re M, Bertolotto A, Di Sapio A (2024) In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting. J Neurol 271(12):7494\u20137501","journal-title":"J Neurol"},{"key":"9187_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1480676","volume":"15","author":"F Rodr\u00edguez-Jorge","year":"2024","unstructured":"Rodr\u00edguez-Jorge F, Fernandez-Velasco JI, Villarrubia N, Gracia-Gil J, Fernandez E, Meca-Lallana V, D\u00edaz-P\u00e9rez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramio-Torrent\u00e0 L (2024) Biomarkers of response to ocrelizumab in relapsing\u2013remitting multiple sclerosis. Front Immunol 15:1480676","journal-title":"Front Immunol"},{"key":"9187_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103590","author":"T Uphaus","year":"2021","unstructured":"Uphaus T, Steffen F, Muthuraman M, Ripfel N, Fleischer V, Groppa S, Ruck T, Meuth SG, Pul R, Kleinschnitz C, Ellwardt E (2021) NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103590","journal-title":"EBioMedicine"},{"issue":"8","key":"9187_CR24","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","volume":"141","author":"C Barro","year":"2018","unstructured":"Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli \u00d6, Michalak Z (2018) Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141(8):2382\u20132391","journal-title":"Brain"},{"issue":"5","key":"9187_CR25","first-page":"e595","volume":"6","author":"S Engel","year":"2019","unstructured":"Engel S, Friedrich M, Muthuraman M, Steffen F, Poplawski A, Groppa S, Bittner S, Zipp F, Luessi F (2019) Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS. Neurology: Neuroimmunol Neuroinflammation 6(5):e595","journal-title":"Neurology: Neuroimmunol Neuroinflammation"},{"issue":"10","key":"9187_CR26","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/acn3.52187","volume":"11","author":"E Madill","year":"2024","unstructured":"Madill E, Healy BC, Molazadeh N, Polgar-Turcsanyi M, Glanz BI, Weiner HL, Chitnis T (2024) Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis. Ann Clin Transl Neurol 11(10):2719\u20132730","journal-title":"Ann Clin Transl Neurol"},{"key":"9187_CR27","doi-asserted-by":"publisher","first-page":"103535","DOI":"10.1016\/j.msard.2022.103535","volume":"59","author":"S Thebault","year":"2022","unstructured":"Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, Booth RA, Uccelli A, Freedman MS (2022) High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Multiple Scler Relat disorders 59:103535","journal-title":"Multiple Scler Relat disorders"},{"key":"9187_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105131","volume":"80","author":"S Toscano","year":"2023","unstructured":"Toscano S, Oteri V, Chisari CG, Finocchiaro C, Fermo SL, Valentino P, Bertolotto A, Zappia M, Patti F (2023) Cerebrospinal fluid neurofilament light chains predicts early disease-activity in multiple sclerosis. Mult Scler Relat Disord 80:105131","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"9187_CR29","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1177\/13524585221097296","volume":"28","author":"S Brune","year":"2022","unstructured":"Brune S, H\u00f8gest\u00f8l EA, de S. A. RB, Berg-Hansen P, Beyer MK, Leikfoss IS, Bos SD, Sowa P, Brunborg C, Andorra M, Pulido Valdeolivas I (2022) Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Mult Scler J 28(12):1859\u201370","journal-title":"Mult Scler J"},{"issue":"5","key":"9187_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/1352458514549397","volume":"21","author":"MA Mart\u00ednez","year":"2015","unstructured":"Mart\u00ednez MA, Olsson B, Bau L, Matas E, Calvo \u00c1C, Andreasson U, Blennow K, Romero-Pinel L, Mart\u00ednez-Y\u00e9lamos S, Zetterberg H (2015) Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler J 21(5):550\u201361","journal-title":"Mult Scler J"},{"issue":"8","key":"9187_CR31","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and treatment of multiple sclerosis: a review. JAMA 325(8):765\u201379","journal-title":"JAMA"},{"issue":"9","key":"9187_CR32","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028928","volume":"8","author":"S Klineova","year":"2018","unstructured":"Klineova S, Lublin FD (2018) Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med 8(9):a028928","journal-title":"Cold Spring Harb Perspect Med"},{"key":"9187_CR33","doi-asserted-by":"publisher","first-page":"104209","DOI":"10.1016\/j.msard.2022.104209","volume":"68","author":"J Talbot","year":"2022","unstructured":"Talbot J, Chow HH, Mahler M, Buhelt S, Hansen RH, Lundell H, Vinther-Jensen T, Hellem MN, Nielsen JE, Siebner HR, von Essen MR (2022) Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis. Mult Scler Relat Disord 68:104209","journal-title":"Mult Scler Relat Disord"},{"key":"9187_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104662","author":"A Bar-Or","year":"2023","unstructured":"Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L (2023) Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104662","journal-title":"EBioMedicine"},{"issue":"9","key":"9187_CR35","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Hauser SL (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 77(9):1132\u201340","journal-title":"JAMA Neurol"},{"key":"9187_CR36","doi-asserted-by":"crossref","unstructured":"Fissolo N, Pignolet B, Rio J, Vermersch P, Ruet A, Des\u00e8ze J, Labauge P, Vukusic S, Papeix C, Martinez-Almoyna L, Tourbah A. Serum neurofilament levels and PML risk in patients with multiple sclerosis treated with natalizumab. Neurology: Neuroimmunology & Neuroinflammation. 2021 Apr 26;8(4):e1003.","DOI":"10.1212\/NXI.0000000000001003"},{"issue":"2","key":"9187_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1212\/01.WNL.0000041496.58127.E3","volume":"60","author":"MJ Eikelenboom","year":"2003","unstructured":"Eikelenboom MJ, Petzold A, Lazeron RH, Silber E, Sharief M, Thompson EJ, Barkhof F, Giovannoni G, Polman CH, Uitdehaag BM (2003) Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 60(2):219\u201323","journal-title":"Neurology"},{"issue":"8","key":"9187_CR38","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/glia.23594","volume":"67","author":"EJ van Bodegraven","year":"2019","unstructured":"van Bodegraven EJ, van Asperen JV, Robe PA, Hol EM (2019) Importance of GFAP isoform-specific analyses in astrocytoma. Glia 67(8):1417\u20131433","journal-title":"Glia"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09187-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09187-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09187-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:06:17Z","timestamp":1783407977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09187-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["9187"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09187-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"580"}}